Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

687
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
687
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

363
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
363
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
Neural Regulation01:37

Neural Regulation

39.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.8K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

4.6K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
4.6K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

2.9K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Azathioprine for the treatment of early Parkinson's disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial.

The Lancet. Neurology·2025
Same author

Phase 1, randomized trials of MEDI1341: cerebrospinal fluid free α-synuclein lowered by >50.

Brain communications·2025
Same author

The profile of gastrointestinal dysfunction in prodromal to late-stage Parkinson's disease.

NPJ Parkinson's disease·2025
Same author

Validation of a 5-Year Prognostic Model for Parkinson's Disease.

Movement disorders clinical practice·2024
Same author

B lymphocyte responses in Parkinson's disease and their possible significance in disease progression.

Brain communications·2023
Same author

T lymphocyte senescence is attenuated in Parkinson's disease.

Journal of neuroinflammation·2021

Related Experiment Video

Updated: Sep 2, 2025

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
06:07

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

1.7K

B Lymphocytes in Parkinson's Disease.

Kirsten M Scott1,2

  • 1Department of Neurology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Journal of Parkinson'S Disease
|August 8, 2022
PubMed
Summary

B lymphocytes, crucial for immunity, are implicated in Parkinson's disease (PD) pathology. Research suggests these cells, particularly regulatory B cells, may offer protection against PD progression.

Keywords:
B lymphocytesParkinson’s diseasealpha-synuclein antibodiesinflammation

More Related Videos

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
12:49

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

7.6K
Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
14:45

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein

Published on: July 29, 2022

6.1K

Related Experiment Videos

Last Updated: Sep 2, 2025

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
06:07

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

1.7K
Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
12:49

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

7.6K
Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
14:45

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein

Published on: July 29, 2022

6.1K

Area of Science:

  • Immunology
  • Neuroscience
  • Pathology

Background:

  • B lymphocytes perform diverse immune functions beyond antibody production, including antigen presentation and immune regulation.
  • Parkinson's disease (PD) exhibits inflammation in both the central nervous system and periphery, suggesting immune cell involvement.
  • B lymphocytes, including distinct subsets, have roles in PD that are less understood compared to T cells and monocytes.

Purpose of the Study:

  • To explore the multifaceted role of B lymphocytes in the context of Parkinson's disease.
  • To investigate the impact of B cell alterations and their subsets in PD pathogenesis.
  • To identify potential therapeutic strategies targeting B cells for PD treatment.

Main Methods:

  • Review of existing literature on B cell functions and their involvement in neuroinflammatory diseases.
  • Analysis of studies examining B lymphocyte populations and their subsets in Parkinson's disease patients.
  • Examination of evidence regarding antibodies to alpha-synuclein and their role in PD.

Main Results:

  • B lymphocytes are found to be decreased in Parkinson's disease, potentially due to a reduction in regulatory B cell subsets.
  • Regulatory B cells show evidence of being protective in Parkinson's disease.
  • Antibodies targeting alpha-synuclein may play a role in early Parkinson's disease, with possible increases observed.

Conclusions:

  • B lymphocytes are significantly involved in Parkinson's disease, with complex roles influenced by various subsets.
  • Further research into meningeal and calvarial B cells, alongside clinical cohort studies, is warranted.
  • Targeting B cells presents a promising therapeutic avenue for Parkinson's disease.